Experiência clínica com omalizumab na consulta de asma grave

Abstract

The current analysis shows evidence that omalizumab is successful in improving asthma control as an add-on therapy GINA step 5 treatment.

Real-life efficacy and safety of omalizumab in Portuguese patients with persistent uncontrolled asthma

“…Furthermore, there were reductions in the clinically significant and severe clinically significant exacerbations similar to those observed in the global registry and other real-life studies in Portugal. 7,11 Clinically meaningful improvements in important outcomes (ACT TM and mini-AQLQ) together with over 90% of patients showing ≥0.5 score increase at Month 24 were also registered. These findings are comparable with another Portuguese study where there has been progress for ACT TM .…”

Long-Term Omalizumab Treatment: A Multicenter, Real-Life, 5-Year Trial

“…Our study ( n = 465) is the second-largest after the “France real-life study” [21] ( n = 767) of the studies presenting real-life data from a single country, and the only one to present the results of 5 years of follow-up. Previous studies have mostly covered a period of ≤3 years [11-23, 25]; 1 other study presents 4-year data [24]. We consider that our study presents long-term data with an adequate number of patients.…”

“…The rates of decrease were 72, 64, and 55% for years 1, 3, and 5, respectively. Other real-life studies have reported 1st year decrease rates of 45.7% [25] and 80% [13, 15]. There are no studies to directly compare our year 3 and year 5 results, but the closest are a year 2 result of 73.2% [27] and a year 4 result of 70% [24].…”

“…The median ACT score before omalizumab use was 9 but this increased markedly after the first year (median ACT 21). Real-life studies also evaluated the day-and-night symptoms ratio directly [12, 25], in addition to using questionnaires such as the ACT [15, 24, 25, 27] and the Asthma Control Questionnaire [18, 28] to evaluate asthma symptom control. The general result of these studies is a marked decrease in symptoms and an improvement in the relevant scores, similar to in our study.…”